Baeker T R, Rothstein T L
Clin Immunol Immunopathol. 1986 May;39(2):285-97. doi: 10.1016/0090-1229(86)90092-9.
Therapeutic trials of anti-immunoglobulin antibody have produced a wide range of responses in attempts to control the growth of human B lymphoid neoplasms. This variability might reflect differences in intrinsic functional characteristics of malignant B lymphocytes that determine susceptibility to anti-immunoglobulin-mediated regulation of growth. To characterize B-lymphocyte malignancies, tissue samples from 24 patients were studied during short-term culture in vitro. Malignant B lymphocytes were stimulated to proliferate by the T-independent mitogens lipopolysaccharide, cytochalasin B, and Staphylococcus aureus that bears protein A. The effects of monoclonal mouse anti-human IgM on mitogen-induced malignant lymphocyte proliferation were then assessed. Mitogen-induced responses of malignant lymphocytes from three patients were abrogated by 2 micrograms/ml monoclonal anti-human IgM. Proliferation was also abrogated by polyclonal goat anti-IgM antiserum but proliferative responses were not affected by control monoclonal antibody. Further study showed that anti-immunoglobulin-mediated inhibition of proliferation was not dependent on Fc-determined interactions, nor was it dependent on the presence of T lymphocytes. These results indicate that a subset of human B-lymphocyte malignancies are susceptible to inhibition of proliferation mediated by anti-IgM.
抗免疫球蛋白抗体的治疗试验在控制人类B淋巴细胞肿瘤生长的尝试中产生了广泛的反应。这种变异性可能反映了恶性B淋巴细胞内在功能特征的差异，这些差异决定了对抗免疫球蛋白介导的生长调节的易感性。为了表征B淋巴细胞恶性肿瘤，在体外短期培养期间研究了24例患者的组织样本。通过T细胞非依赖性丝裂原脂多糖、细胞松弛素B和带有蛋白A的金黄色葡萄球菌刺激恶性B淋巴细胞增殖。然后评估单克隆小鼠抗人IgM对丝裂原诱导的恶性淋巴细胞增殖的影响。2微克/毫升的单克隆抗人IgM消除了三名患者的恶性淋巴细胞的丝裂原诱导反应。多克隆山羊抗IgM抗血清也消除了增殖，但对照单克隆抗体不影响增殖反应。进一步研究表明，抗免疫球蛋白介导的增殖抑制不依赖于Fc决定的相互作用，也不依赖于T淋巴细胞的存在。这些结果表明，一部分人类B淋巴细胞恶性肿瘤易受抗IgM介导的增殖抑制作用的影响。
